Cargando…

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials

INTRODUCTION: Most Alzheimer’s disease (AD) clinical trials enroll participants multinationally. Yet, few data exist to guide investigators and sponsors regarding the types of patients enrolled in these studies and whether participant characteristics vary by region. METHODS: We used data derived fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grill, Joshua D, Raman, Rema, Ernstrom, Karin, Aisen, Paul, Dowsett, Sherie A, Chen, Yun-Fei, Liu-Seifert, Hong, Hake, Ann Marie, Miller, David S, Doody, Rachelle S, Henley, David B, Cummings, Jeffrey L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481112/ https://www.ncbi.nlm.nih.gov/pubmed/26120368 http://dx.doi.org/10.1186/s13195-015-0122-5

Ejemplares similares

Alzheimer’s disease progression by geographical region in a clinical trial setting
por: Henley, David B, et al.
Publicado: (2015)

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
por: Doody, Rachelle S, et al.
Publicado: (2015)

Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials
por: Bernstein, Olivia M., et al.
Publicado: (2021)

Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment
por: Kirn, Dylan R., et al.
Publicado: (2023)

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
por: Raman, Rema, et al.
Publicado: (2021)

Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials
por: Grill, Joshua D, et al.
Publicado: (2010)

Attitudes about involvement in hypothetical clinical trial protocols in Mexican and Mexican-American at risk for autosomal dominant Alzheimer’s disease
por: Zuno-Reyes, Angélica, et al.
Publicado: (2022)

Drug development in Alzheimer’s disease: the path to 2025
por: Cummings, Jeffrey, et al.
Publicado: (2016)

The Alzheimer's Disease Cooperative Study Prevention Instrument Project: Longitudinal Outcome of Behavioral Measures as Predictors of Cognitive Decline
por: Banks, Sarah Jane, et al.
Publicado: (2014)

On the path to 2025: understanding the Alzheimer’s disease continuum
por: Aisen, Paul S., et al.
Publicado: (2017)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Early-stage Alzheimer disease: getting trial-ready
por: Aisen, Paul S., et al.
Publicado: (2022)

Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)
por: Walter, S., et al.
Publicado: (2020)

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program
por: Cummings, Jeffrey L., et al.
Publicado: (2018)

Assessing quality of life in Alzheimer's disease: Implications for clinical trials
por: Kahle-Wrobleski, Kristin, et al.
Publicado: (2016)

Defining Mild Stroke: Outcomes Analysis of Treated and Untreated Mild Stroke Patients
por: Spokoyny, Ilana, et al.
Publicado: (2015)

Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022)

Recruiting to preclinical Alzheimer's disease clinical trials through registries
por: Grill, Joshua D.
Publicado: (2017)

Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial
por: Kellar, Derek, et al.
Publicado: (2022)

Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials
por: Langford, O., et al.
Publicado: (2020)

Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease
por: Baldaranov, Dobri, et al.
Publicado: (2023)

Recruitment and retention of underrepresented populations in Alzheimer's disease research: A systematic review
por: Gilmore-Bykovskyi, Andrea L., et al.
Publicado: (2019)

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies
por: Smith, Timothy, et al.
Publicado: (2020)

TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology
por: Jimenez-Maggiora, G.A., et al.
Publicado: (2020)

Rapid Web-Based Recruitment of Patients With Psoriasis: Multinational Cohort Study
por: Duus Holm, Zacharias, et al.
Publicado: (2023)

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
por: Wessels, Alette M., et al.
Publicado: (2023)

Patient Engagement: The Fundació ACE Framework for Improving Recruitment and Retention in Alzheimer’s Disease Research
por: Boada, Mercè, et al.
Publicado: (2018)

Recruitment and retention of lung volume
por: Lapinsky, Stephen E
Publicado: (2003)

Predicting progression of Alzheimer's disease
por: Doody, Rachelle S, et al.
Publicado: (2010)

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
por: Sabbagh, Marwan, et al.
Publicado: (2013)

Alzheimer’s Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer’s Clinical Trial Consortium Sites
por: Rhodus, Elizabeth K., et al.
Publicado: (2022)

Infusing Representativeness and Cultivating Harmonization in Alzheimer’s Trials: World Wide FINGERS
por: Raman, Rema, et al.
Publicado: (2021)

Geographical diversification using ETFs: Multinational evidence from COVID-19 pandemic
por: Yousefi, Hamed, et al.
Publicado: (2022)

Modeling the course of Alzheimer's disease to improve clinical trials: symposium report
por: Spiegel, René, et al.
Publicado: (2013)

Correction: Predicting progression of Alzheimer's disease
por: Doody, Rachelle S, et al.
Publicado: (2010)

Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study
por: Inusa, Baba Psalm Duniya, et al.
Publicado: (2019)

Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials
por: Ritchie, Marina, et al.
Publicado: (2023)

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
por: Ferris, Steven, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o2060ii4ndi5iaaaunbpu45fq5